Nebenwirkungen · Leqembi
LEQEMBI 100 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 9–10
HOS-150412 · Präparat HOS-100312
9 3 Occurred 24 hours after infusion. 4 ARIA: Includes radiographic ARIA-E, symptomatic ARIA-E, radiographic ARIA-H and symptomatic ARIA-H. 5 ARIA-H: Includes radiographic ARIA-H and symptomatic ARIA-H. 6 ARIA-H: Amyloid related imaging abnormality-microhaemorrhage and haemosiderin deposit; Superficial siderosis of central nervous system, and Cerebellar microhaemorrhage. 7 Includes common symptom of headache; uncommon symptoms of confusion, visual changes (diplopia, glare, vision blurred, visual acuity reduced, visual impairment), dizziness, nausea, gait difficulty and seizures. 8 ARIA-E: Includes radiographic ARIA-E and symptomatic ARIA-E. 9 ARIA-E is common in the indicated population and very common in the homozygote population. 10 Includes infusion related reaction and infusion site reaction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-05T11:45:00Z · SHA-256 b5b97a1240d6c003d96cd8b3294bef8b3b5d33af33f6be54cfceee548b126f2d · Passage f0ed23d248967c940248e12def1824f643484bbd48ca40bd28404e9911a7ff9f · Zeichen 3580–4424 im Abschnitt